^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR181B1 (MicroRNA 181b-1)

    i
    Other names: MIR181B1, MicroRNA 181b-1, Hsa-MiR-181b-3p, Hsa-MiR-181b-5p, Hsa-Mir-181b-1, Hsa-Mir-181-P2a, MIMAT0000257, MIMAT0022692, Mir-181b-1, MIRN181B1, MI0000270
    Associations

    News

    Trials
    4d
    Cancer-associated fibroblasts promote immune evasion in pancreatic cancer via miR-181b-5p/STING/LGALS1 pathway. (PubMed, Cancer Lett)
    The upregulated LGALS1 is then secreted via SUSD2 assistance, ultimately suppressing CD8+ T cell function and inducing apoptosis. Our findings define a stromal-immune axis in pancreatic cancer, linking miR-181b-5p from CAFs to the establishment of an immune-suppressive niche via the STING pathway in tumor cells, thereby revealing this cascade as a targetable mechanism to counteract immune evasion.
    Journal
    |
    CD8 (cluster of differentiation 8) • LGALS1 (Galectin 1) • STING (stimulator of interferon response cGAMP interactor 1) • MIR181B1 (MicroRNA 181b-1) • YY1 (YY1 Transcription Factor)
    2ms
    miRNA as a Prognostic Marker in Small Lung Cell Carcinoma. (PubMed, Genes (Basel))
    In particular, strategies that restore or inhibit miRNA activity using mimics or antagomiRs show promise in improving drug sensitivity and complementing current treatment options. Overall, emerging evidence supports the integration of miRNA profiling into precision oncology for SCLC, with the aim of refining diagnosis, risk assessment and therapeutic decision-making.
    Review • Journal • PARP Biomarker
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • MIR200B (MicroRNA 200b) • TGFB1 (Transforming Growth Factor Beta 1) • MIR100 (MicroRNA 100) • MIR7 (MicroRNA 7) • MIR335 (MicroRNA 335) • MIR494 (MicroRNA 494) • MIR495 (MicroRNA 495) • MIR181B1 (MicroRNA 181b-1) • MIR22 (MicroRNA 22) • MIR30A (MicroRNA 30a) • MIR134 (MicroRNA 134)
    2ms
    Retraction: MicroRNA-181b Inhibits Cellular Proliferation and Invasion of Glioma Cells via Targeting Sal-Like Protein 4. (PubMed, Oncol Res)
    [This retracts the article DOI: 10.3727/096504016X14791732531006.].
    Journal
    |
    SALL4 (Spalt Like Transcription Factor 4) • MIR181B1 (MicroRNA 181b-1)
    4ms
    Integrated assessment of non-invasive diagnostic tools for bladder cancer: a network meta-analysis. (PubMed, Front Oncol)
    Specific microRNAs and combined detection strategies demonstrated robust diagnostic potential, providing a promising alternative to cystoscopy, particularly for early screening and patient monitoring. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251018161.
    Retrospective data • Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • MIR181B1 (MicroRNA 181b-1)
    5ms
    Diagnostic and prognostic potential of microRNA profiles in endometrioid endometrial cancer. (PubMed, Sci Rep)
    We showed that miRNAs have good diagnostic sensitivity for identifying EEC and EC grading. In addition, miRNA improved the ability to discriminate between ECs of different grades.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • PTEN (Phosphatase and tensin homolog) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MIR200B (MicroRNA 200b) • MIR21 (MicroRNA 21) • MIR200C (MicroRNA 200c) • MIR429 (MicroRNA 429) • MIR30B (MicroRNA 30b) • MIR324 (MicroRNA 324) • MIR543 (MicroRNA 543) • MIR96 (MicroRNA 96) • Let-7c (MicroRNA Let-7c) • MIR126 (MicroRNA 126) • MIR141 (MicroRNA 141) • MIR182 (MicroRNA 182) • MIR18A (MicroRNA 18a) • MIR129 (MicroRNA 129) • MIR129-2 (MicroRNA 129-2) • MIR130A (MicroRNA 130a) • MIR181B1 (MicroRNA 181b-1) • MIR183 (MicroRNA 183) • MIR203A (MicroRNA 203a) • MIR205 (MicroRNA 205) • MIR217 (MicroRNA 217) • MIR30C • MIRLET7E (MicroRNA Let-7e)
    5ms
    Integrated miRNA-mRNA Analyses of Triple-Negative Breast Cancer in Black and White Patients with or Without Obesity. (PubMed, Int J Mol Sci)
    Pathway enrichment analysis highlighted KRAS, ESR1, ESR2, RAB10, TNRC6C, and NCAN as the most commonly differentially expressed in EA, whereas ERBB4, PLCB1, and SERPINE1 were most frequently in AA. These findings highlight the importance of considering race-specific miRNA-mRNA signatures in understanding TNBC in the context of obesity, offering insights into biomarker-driven patient stratification for targeted therapeutic strategies.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • SERPINE1 (Serpin Family E Member 1) • MIR143 (MicroRNA 143) • MIR424 (MicroRNA 424) • CDC25B (Cell Division Cycle 25B) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • MIR130A (MicroRNA 130a) • MIR148A (MicroRNA 148a) • MIR181B1 (MicroRNA 181b-1) • MIR195 (MicroRNA 195) • MIR204 (MicroRNA 204) • MIR30A (MicroRNA 30a) • NCBP1 (Nuclear Cap Binding Protein Subunit 1) • RAB10 (RAB10, Member RAS Oncogene Family)
    7ms
    Differential Expression of MicroRNAs in the Colorectal Serrated Neoplasia Pathway and Adenoma-Carcinoma Sequence. (PubMed, Gastroenterol Res Pract)
    These findings indicate that the SSL and AD pathways exhibit distinct miRNA expression dynamics during colorectal tumorigenesis, with the AD lineage showing a progressive increase in oncogenic miRNAs and the SSL series exhibiting selective downregulation or plateauing, particularly in invasive lesions. The differential expression of miR-20a, miR-21, miR-93, and miR-181b was presumed to be related to (epi)genetic alterations among serrated neoplasia and AD-carcinoma routes.
    Journal
    |
    MIR21 (MicroRNA 21) • MIR181B1 (MicroRNA 181b-1) • MIR20A (MicroRNA 20a) • MIR93 (MicroRNA 93)
    7ms
    Vitamin D-regulated miRNA expression in tumoral and normal adjacent tissue of localized gastric cancer patients: the impact on survival and time to relapse. (PubMed, Transl Cancer Res)
    Additionally, miRNA expression patterns in NAT may indicate a predisposition to tumor recurrence. The study concludes that miRNA dysregulation in non-neoplastic gastric mucosa suggests these tissues may be cancer-prone environments.
    Journal
    |
    MIR143 (MicroRNA 143) • MIR106B (MicroRNA 106b) • MIR145 (MicroRNA 145) • MIR181A1 (MicroRNA 181a-1) • MIR181B1 (MicroRNA 181b-1) • MIR181C (MicroRNA 181c) • MIR99B (MicroRNA 99b)
    8ms
    Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia. (PubMed, Blood Adv)
    Furthermore, we report that ibrutinib elicits a reduction in c-Fos protein levels after 72 hours of treatment, a transcription factor that we demonstrated to be implicated in the regulatory control of miR-181a and miR-181b, thereby establishing a regulatory feedback loop linked to cell death. These findings provide further insight into how ibrutinib affects leukemic cells in CLL patients and offer a basis for investigating potential resistance mechanisms.
    Journal
    |
    FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2) • MIR181A1 (MicroRNA 181a-1) • MIR181B1 (MicroRNA 181b-1)
    |
    Imbruvica (ibrutinib)
    8ms
    Exploring the Shared miRNA-mRNA Signature Network Between Helicobacter pylori Infection and Gastric Cancer: A Comparative Study. (PubMed, Curr Microbiol)
    Moreover, along with the TCGA-validated hydroxyacyl-CoA dehydrogenase (HADH), the epithelial splicing regulatory protein-2 (ESRP2) and dihydrolipoamide branched chain transacylase E2 (DBT) were downregulated in both conditions, possibly attributed to the effect of functional hDEmiRs targeting them. Our findings offer potential candidates for miRNA-directed therapeutics in these pathologies.
    Clinical • Journal
    |
    MIR21 (MicroRNA 21) • Let-7c (MicroRNA Let-7c) • MIR25 (MicroRNA 25) • MIR15A (MicroRNA 15a) • MIR181B1 (MicroRNA 181b-1) • MIR204 (MicroRNA 204) • MIR98 (MicroRNA 98)
    8ms
    Comparison Bioinformatic Analysis of Extracellular Vesicles-Related Genes and MicroRNAs in Breast Cancer. (PubMed, Int J Mol Sci)
    CD36, DAB2, CXCL14, TIMP1, miR-222-3p, and miR-181b-5p may serve as biomarkers for BC pathogenesis and potential therapeutic targets. Further studies are needed to validate these findings.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD36 (thrombospondin receptor) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • MARCKS (Myristoylated Alanine Rich Protein Kinase C Substrate) • MIR181B1 (MicroRNA 181b-1) • MIR222 (MicroRNA 222)
    8ms
    Omics Study of Ovarian Malignancies: From Urine Metabolomic Profile to Minimally Invasive MicroRNA Markers (PubMed, Mol Biol (Mosk))
    Thus, significant metabolomic imbalance in the urine was observed in the OC patients and was associated with changes in the levels of microRNAs that regulate the signaling pathways of the metabolites. The 26 compounds with abnormal concentrations and the levels of the microRNAs miR-33b-5p, miR-423-5p, miR-6843-3p, miR-4668-3p, miR-30c-5p, miR-6743-5p, miR-4742-5p, miR-1207-5p, and miR-17-5p in the urine were considered to be suitable as noninvasive diagnostic markers of OC.
    Journal • Metabolomic study
    |
    MIR27A (MicroRNA 27a) • MIR17 (MicroRNA 17) • MIR23A (MicroRNA 23a) • MIR370 (MicroRNA 370) • MIR1207 (MicroRNA 1207) • MIR181A1 (MicroRNA 181a-1) • MIR181B1 (MicroRNA 181b-1) • MIR196B (MicroRNA 196b) • MIR19A (MicroRNA 19a) • MIR208A (MicroRNA 208a) • MIR29A (MicroRNA 29a) • MIR30C • MIR330 (MicroRNA 330) • MIR423 (MicroRNA 423) • MIR4742 (MicroRNA 4742) • MIR653 (MicroRNA 653) • MIRLET7B (MicroRNA Let-7b)